$ICHR

MacKenzie Iain sold $653K of ICHR

MacKenzie Iain sold 9,933 shares of ICHOR HOLDINGS, LTD. (ICHR) at an average of $65.76 ($65.19–$68.14, $0.65M total) across 4 trades on 2026-08-18 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · MacKenzie Iain
Published Aug 20, 2026, 9:27 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 20, 2026, 9:32 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$ICHR
Bearish
medium confidence
Mentioned
$ICHR
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ICHRBearishLow
01

Why it matters

The disclosed sale adds a data point for short‑term sentiment but is unlikely to drive significant price movement.

02

Market read

Primary insider sale filing; modest relevance for traders monitoring ICHOR.

03

What to watch

The director retained 122,427 shares, indicating continued confidence in the company.

Relevance 4/10Novelty 4/10Timing: filed today

Background

SEC Form 4 filings disclose insider transactions. This filing reports a director's open‑market sale under a 10b5‑1 plan.

Company-level read

Ticker impact

$ICHRBearishMedium confidence
Context

Director MacKenzie Iain sold 9,933 shares for $653,176 on 2026-08-18 via a 10b5‑1 plan.

Expected impact

Potential short‑term dip of 1‑2% as the market digests the sale.

Evidence & confidence

A $653k sale by a director is a primary Form 4 disclosure but the amount is modest for a listed biotech, limiting material impact.

Market effects

Minimal effect on the broader biotech sector; insider sales are common and rarely shift sector sentiment.

No notable regional impact; the filing is specific to ICHOR.

Limited global relevance; only relevant to investors tracking ICHOR.

Counterpoint

The sale could be a routine liquidity move under a pre‑arranged plan, not a bearish signal.

Key entities

  • MacKenzie Iain

    Director of ICHOR Holdings who executed the sale.

  • ICHR

    ICHOR Holdings, Ltd., a biotech listed on NASDAQ.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$ICHRMed

What Ichor (ICHR) Said on Its Q3 Earnings Call

Ichor (ICHR) reported Q3 earnings, noting supply constraints in high-end applications but improved revenue linearity. Q4 revenue is forecasted at $345M-$365M, with 8% sequential growth at the midpoint. Gross margin is expected at 16.5%±0.5%, and EPS at $0.65-$0.75. The company is investing in capacity expansion to support $3B revenue by 2027, with increased hiring and customer inventory backstopping.

$ICHRHighAI 9/10

Why is Ichor Holdings stock gaining today?

Ichor Holdings (ICHR) stock rose 0.2% after reporting Q3 2026 earnings of $0.63 per share, beating estimates by $0.18. Revenue grew 37% YoY to $328.7M, slightly missing expectations. The company guided Q4 EPS to $0.65-$0.75, well above consensus. Gross margin expanded to 16.0% from 5.1% YoY, but free cash flow turned negative.

$ICHRMed

Ichor Holdings, Ltd. Announces Third Quarter 2026 Financial Results

ICHOR HOLDINGS, LTD. (ICHR) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Ichor Holdings, Ltd. Announces Third Quarter 2026 Financial Results FREMONT, Calif., November 2, 2026–Ichor Holdings, Ltd. (NASDAQ: ICHR), a leader in the design, engineering, and manufacturing of critical fluid delivery subsystems and components for semiconductor ca